Oramed Pharmaceuticals Inc. (ORMP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Oramed Pharmaceuticals Inc. (ORMP:NASDAQ), powered by AI.

Current Price
$3.77
P/E Ratio
2.4
Market Cap
156M
Sector
Healthcare
What is the Oramed Pharmaceuticals Inc. stock price forecast?

Oramed Pharmaceuticals Inc. is currently trading at $3.77. View real-time AI analysis on Alpha Lenz.

What is Oramed Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Oramed Pharmaceuticals Inc. on Alpha Lenz.

What is Oramed Pharmaceuticals Inc.'s P/E ratio?

Oramed Pharmaceuticals Inc.'s P/E ratio is 2.4.

Oramed Pharmaceuticals Inc.

NASDAQ · ORMP
$3.77-0.07(-1.82%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Oramed Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Oramed Pharmaceuticals Inc. trades at a P/E of 2.4 (undervalued) with strong ROE of 37.0%.

Ask for details

Company Overview

Oramed Pharmaceuticals Inc. is a biotechnology company focused on the research and development of oral drug delivery systems. The primary purpose of the company is to transform injectable treatments into oral forms, thereby aiming to enhance patient convenience and compliance. A notable highlight of Oramed's innovation is its proprietary Protein Oral Delivery (POD) technology, which facilitates the oral administration of proteins that traditionally require injections. This innovative approach has significant implications for therapeutics, particularly in areas like diabetes treatment, where oral insulin could potentially revolutionize disease management. Headquartered in Jerusalem, Israel, Oramed Pharmaceuticals Inc. holds a significant position in the healthcare sector, pushing forward the boundaries of medical treatment options through its cutting-edge research. Its development pipeline showcases the potential to reshape how chronic illnesses are managed, emphasizing the company's role as a pioneer in the oral delivery of biologics in the financial and healthcare markets.

CEOMr. Nadav Kidron Esq.
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

$156.09MMarket Cap
$2.00MRevenue
0.00Shares Out
0Employees

Margins

0.65%Gross
-612.10%EBITDA
-754.40%Operating
3766.20%Pre-Tax
3200.80%Net

Valuation

2.44P/E
0.78P/B
78.04EV/Sales
-9.06EV/EBITDA
-14.09P/FCF

Growth (CAGR)

-9.55%Rev 3Yr
-5.90%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

33.16%ROA
37.02%ROE
39.01%ROIC

Financial Health

$45.95MCash & Cash Equivalents
$-14.83MNet Debt
15.58%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Oramed Pharmaceuticals Inc. (ticker: ORMP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). Market cap is $156M.

The current price is $3.77 with a P/E ratio of 2.44x and P/B of 0.78x.

ROE is 37.02% and operating margin is -754.40%. Annual revenue is $2M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Oramed Pharmaceuticals Inc. (ORMP) Stock Forecast 2026 $3.77 — Price, Financials & Analyst Targets | Alpha Lenz